Rubius Therapeutics Valuation
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Rubius Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Rubius Therapeutics from analyzing the company fundamentals such as Shares Outstanding of 90.4 M, return on equity of -1.85, and Shares Owned By Institutions of 72.61 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Rubius Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Rubius Therapeutics is based on 3 months time horizon. Increasing Rubius Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rubius Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rubius Pink Sheet. However, Rubius Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.083 | Real 0.0789 | Hype 0.08 |
The intrinsic value of Rubius Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rubius Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rubius Therapeutics helps investors to forecast how Rubius pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rubius Therapeutics more accurately as focusing exclusively on Rubius Therapeutics' fundamentals will not take into account other important factors: Rubius Therapeutics Total Value Analysis
Rubius Therapeutics is at this time forecasted to have valuation of 22.18 M with market capitalization of 7.5 M, debt of 76.15 M, and cash on hands of 140.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rubius Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
22.18 M | 7.5 M | 76.15 M | 140.71 M |
Rubius Therapeutics Asset Utilization
One of the ways to look at asset utilization of Rubius is to check how much profit was generated for every dollar of assets it reports. Rubius Therapeutics holds a negative application of assets of -0.47 pct., losing $0.004663 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rubius Therapeutics shows how discouraging it operates for each dollar spent on its assets.Rubius Therapeutics Ownership Allocation
Rubius Therapeutics owns a total of 90.4 Million outstanding shares. The majority of Rubius Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rubius Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rubius Therapeutics. Please pay attention to any change in the institutional holdings of Rubius Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rubius Therapeutics Profitability Analysis
Net Loss for the year was (179.67 M) with profit before overhead, payroll, taxes, and interest of 0.About Rubius Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Rubius Therapeutics. We calculate exposure to Rubius Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rubius Therapeutics's related companies.Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of patients with severe diseases. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Rubius Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people.
8 Steps to conduct Rubius Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rubius Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rubius Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rubius Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rubius Therapeutics' revenue streams: Identify Rubius Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rubius Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rubius Therapeutics' growth potential: Evaluate Rubius Therapeutics' management, business model, and growth potential.
- Determine Rubius Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rubius Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Rubius Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 90.4 M | |
| Retained Earnings | -856.7 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |